Kardigan Announces Appointment of Kristin Reinke to its Board of DirectorsBusiness Wire · Sep 30, 2026
Kardigan, Inc. (NASDAQ:KARD) Stock Has Consensus Price Target of $42.25 According to AnalystsDefense World · Sep 30, 2026
Kardigan: Funded Precision Cardiology Offers More Than Pipeline DiversificationSeeking Alpha · Sep 13, 2026
Kardigan to Present at Two September Investor ConferencesBusiness Wire · Sep 2, 2026
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business UpdatesGuruFocus · Aug 11, 2026
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business UpdatesBusiness Wire · Aug 11, 2026Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E.